Merck pauses 2 more trials of backbone HIV drug over red flag, raising doubts about multipronged R&D strategy Recursion loops in Roche, Genentech for multibillion-dollar AI drug discovery deal Watch out, Pfizer and Alnylam. AstraZeneca wades deeper into rare diseases with Ionis tie-up Female doctors earn an estimated $2M less than their male counterparts over a 40-year career: study Former FDA head Hahn takes helm of cancer blood test maker Harbinger Health 'Don't check yourself when you come to work': Being openly LGBTQ+ in a scientist-led industry GlaxoSmithKline and Vir's sotrovimab stands up to omicron despite other COVID antibodies falling short Freenome one-ups itself with $300M from GV, Roche and more to expand cancer blood test platform Reveleer raises $65M for payer-focused data analytics platform, eyes acquisitions in interoperability, NLP tools November sees Sanofi-Regeneron dethroned after 6-month rule over TV ad spender list Experts weigh in on addressing mental health in seniors, mothers Corbus poaches Takeda's oncology leader as it beefs up early-stage pipeline following three trial failures Alvotech, battling AbbVie over its Humira biosim, raises $450M and tees up Nasdaq debut Featured Story | By Nick Paul Taylor Are the foundations of Merck’s broad HIV development program crumbling? Having already paused combination work in response to a red flag, Merck has now temporarily stopped enrollment in phase 3 studies that are testing the backbone of its HIV strategy as a monotherapy. read more |
| |
|---|
|
| | The PerkinElmer Biotech Bundle is deployed via Amazon CloudFormation and provides the most advanced analytical package for drug discovery available today. Affordable and easy to get started. Learn more. |
Top Stories By Conor Hale The artificial intelligence-powered drug designer Recursion signed on to a wide-ranging collaboration with Roche and its Genentech division. Starting with a hefty $150 million upfront payment, the molecule-mining deal allows for up to 40 individual projects split between the two drugmakers in neurology and cancer over the next decade. read more By Angus Liu Just months after wrapping up the Alexion acquisition, AstraZeneca is beefing up its newly established rare disease portfolio with a collaboration with Ionis Pharmaceuticals, targeting a condition where Pfizer and Alnylam are also competing. read more By Susan Kreimer “Gender pay gaps like this, which are large when viewed cumulatively over a lifetime, send the wrong market signal,” senior author Anupam B. Jena, M.D., Ph.D., said. “We want to be encouraging, not discouraging, the best women and men to enter medicine.” read more By Andrea Park Similar to the technology being developed by fellow cancer-focused liquid biopsy developers Grail and Freenome, Harbinger’s platform will use machine learning and other artificial intelligence software to analyze a standard blood sample to detect biological indicators of cancer before symptoms arise. read more By Kyle LaHucik Biopharma leaders share their stories of coming out over the decades and what it means to have out members of the community in the top echelons of drug development. But being out shouldn't be a prerequisite for fostering safe, welcoming workplaces. read more By Kevin Dunleavy Amid reports that COVID-19 antibody treatments from Regeneron and Eli Lilly lose their effectiveness against the omicron variant, GlaxoSmithKline and Vir Biotechnology say the antibody drug is effective against omicron’s full range of mutations. read more By Andrea Park In what has become an annual tradition for Freenome, the developer of a liquid biopsy platform for early cancer detection closed yet another venture capital megaround, sending its total fundraising tally surging to more than $800 million in just seven years. read more By Rebecca Torrence Reveleer, a cloud-based platform helping payers analyze member and provider data, landed $65 million in a funding round led by Oak HC/FT. The company uses machine learning to help government-sponsored payers manage risk adjustment and quality improvement in-house. read more By Sharon Klahr Coey How the mighty have fallen. Regeneron and Sanofi's IL-4/13 immunology drug, Dupixent, has reigned the monthly top ad-spender charts since May but tumbled to No. 7 in November. With five new entries, five of October's drugs were kicked out, at least for now. read more By Anastassia Gliadkovskaya At the Summit on Mental Health by the Association of Healthcare Journalists, experts weighed in on the question of social isolation and the COVID-19 pandemic, health disparities and creative ways to bring care to communities that need it most. read more By Kyle LaHucik With multiple mid- and late-stage failures of its only clinical-stage compound, Corbus Pharmaceuticals is attempting to move forward with earlier-stage assets it in-licensed this summer. So the biopharma hired Takeda oncology leader Rachael Brake as chief scientific officer to lead those efforts. read more By Fraiser Kansteiner Alvotech's plans to go public come shortly after the company escaped a Humira trade secrets theft lawsuit. Separately, Alvotech has sued AbbVie in hopes of ending the pharma juggernaut's "wrongful monopoly" on the world's best-selling drug, Humira. read more |
